Skip to main content

Table 1 Patient and tumour characteristics in the full cohort (n = 264)

From: Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study

Age  
Mean 67.29
Median 69.00
Range 46-84
Sex  
Female 135 (51.1%)
Male 129 (48.9%)
Location  
Head and neck 17 (14.9%)
Extremities 111 (44.8%)
Dorsal thorax 65 (26.2%)
Frontal thorax 35 (14.1%)
Unknown 16
Clark level  
II 93 (37.7%)
III 103 (41.7%)
IV 44 (17.8%)
V 7 (2.8%)
Unknown 17
Breslow (mm)  
Mean 1.57
Median 0.71
Range 0.08-40.00
Breslow AJCC categories  
< = 1 158 (59.8%)
1-2 36 (13.6%)
2-4 40 (15.2%)
> 4 14 (5.3%)
Unknown 16 (6.1%)
Clinical Stage  
1A 154 (74.4%)
1B 25 (12.1%)
2A 17 (8.2%)
2B 7 (3.4%)
3A 2 (1.0%)
4 2 (1.0%)
Unknown 57
Histological type  
SSM 160 (64.5%)
NMM 53 (21.48%)
LMM 29 (11.7%)
Other 6 (2.4%)
Unknown 16
Ulceration  
Absent 214 (85.9%)
Present 35 (14.%)
Unknown 16
Mitotic count  
< 1/mm2 131(51.8)
> = 1/mm2 122(46.2)
Lymphocytic infiltration  
None-mild 72 (29.0%)
Moderate-high 176 (66.7%)
Unknown 16
Recurrence  
No 217 (82.2%)
Yes 47 (17.8%)
Follow-up (years)  
Mean 7.25
Median 6.88
Range 0.64-17.05
Vital status  
Dead 55 (20,8%)
Alive 219 (79,2%)
Dead from malignant melanoma 28 (10.6%)